---
schema_version: "secwatch.filing_event.v1"
accession: "0001564590-21-059895"
form_type: "8-K"
ticker: "RLAY"
cik: "0001812364"
company_name: "Relay Therapeutics, Inc."
filed_at: "2021-12-09T23:59:59+00:00"
generated_at: "2026-06-28T02:31:58.843449+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.3
calibrated_materiality_score: 0.3
confidence: "high"
source: SEC EDGAR
---

# Director Deep Nishar resigns from Relay Therapeutics board

## Summary
- Dipchand (Deep) Nishar resigned as Class III director effective December 8, 2021.
- Resignation was not due to any dispute or disagreement with the company, management, or board.
- No replacement director has been announced in this filing.

## SEC filing metadata
- accession: 0001564590-21-059895
- form_type: 8-K
- ticker: RLAY
- cik: 0001812364
- company_name: Relay Therapeutics, Inc.
- filed_at: 2021-12-09T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.3
- calibrated_materiality_score: 0.3
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1812364/000156459021059895/0001564590-21-059895-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1812364/000156459021059895/rlay-8k_20211208.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001564590-21-059895
- JSON: https://secwatch.observer/filing/0001564590-21-059895.json
- Plain text: https://secwatch.observer/filing/0001564590-21-059895.txt

## Key facts
- Executive change
  Dipchand (Deep) Nishar resigned as Class III director at Relay Therapeutics, Inc..
  - Action: resigned
  - Role: Class III director
  source text: On and effective as of December 8, 2021, Dipchand (Deep) Nishar tendered his resignation as a Class III director of the board of directors (the “Board”) of Relay Therapeutics, Inc. (the “Company”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1812364/000156459021059895/0001564590-21-059895-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.